Table 2

Published trials of low-dose vasopressin in human septic shock

Reference

Study design (n)

Observed effects

[1]

Case series (5)

A, B, C

[3]

Matched cohort (19)

A, B, D

[9]

Randomized clinical trial versus placebo (10)

A, B

[15]

Case series (16)

A, C

[16]

Case series (50)

A, B, C

[17]

Retrospective case series (38)

A

[18]

Randomized clinical trial: noradrenaline + vasopressin versus noradrenaline (48)

A, B, C, E, F

[19]

Randomized clinical trial: noradrenaline versus vasopressin (24)

B, C, D, F, G

[99]

Cases series (11)

H

[100]

Noradrenaline versus vasopressin (12)

A, F, H

A, significant increase in blood pressure; B, decrease in catecholamines related to an increase in blood pressure; C, increase in urine output; D, low doses of measured vasopressin; E, increase in systemic vascular resistance; F, absence of effect on mesenteric circulation; G, improvement in creatinine clearance; H, hypoperfusion of the gastric mucosa.

Delmas et al. Critical Care 2005 9:212   doi:10.1186/cc2945